Back to News
Market Impact: 0.48
BioMarin's VOXZOGO Hits Phase 3 Growth Endpoint In Hypochondroplasia
Source: Nasdaq
Healthcare & BiotechProduct Launches
BioMarin's Phase 3 CANOPY-HCH-3 trial of VOXZOGO (vosoritide) met its primary endpoint in children with hypochondroplasia. The treatment delivered a statistically significant improvement in annualized growth velocity versus placebo, supporting a potential expansion of VOXZOGO's clinical and commercial opportunity.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.72
Ticker Sentiment
BMRN0.88
More News
- BioMarin at Wells Fargo conference: growth, pipeline and integration
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- Samsung works to draw iPhone users to its foldables even as Apple enters the market
- Oil Tops $100 on Supply Fears, Apple Faces a Big Test
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript